OncoMatch/Clinical Trials/NCT05080010
Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
Is NCT05080010 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies 3 cycles chemotherapy for retinoblastoma.
Treatment: 3 cycles chemotherapy — The purpose of this study is to determine the effect of 3 cycles of chemotherapy(CEV) in the treatment of Stage I enucleated retinoblastoma.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage I
Prior therapy
Must have received: enucleation — study eye
Received enucleation in the study eye
Cannot have received: chemical intervention
History of chemical intervention for retinoblastoma in the study eye
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify